News
AGRX
3.640
-1.62%
-0.060
BRIEF-Agile Therapeutics Received Notice To Regain Compliance With Nasdaq Listing Rule
Reuters · 1d ago
Agile Therapeutics Inc: Current report
Press release · 1d ago
Agile Therapeutics Closes $7.5 Million Public Offering
Agile Therapeutics Closes $7.5 Million Public Offering
MT Newswires · 05/26 03:49
Agile Therapeutics prices $7.5M offering
Seeking Alpha · 05/23 07:52
Agile Therapeutics Prices $7.5 Million Public Offering of Common Stock, Warrants
Agile Therapeutics Prices $7.5 Million Public Offering of Common Stock, Warrants
MT Newswires · 05/23 04:02
BRIEF-Agile Therapeutics Announces Pricing Of $7.5 Million Public Offering
Reuters · 05/23 00:03
A Look Into Healthcare Sector Value Stocks
Benzinga · 05/22 14:43
Agile Therapeutics Inc: [Amend]General form for registration of securities under the Securities Act of 1933
Press release · 05/19 12:21
XBiotech, Impel top healthcare gainers; Intercept, Agile among losers
Seeking Alpha · 05/17 14:03
BRIEF-Agile Therapeutics Says On May 11 Timely Submitted Its Plan To Staff Of Nasdaq To Regain Compliance With Nasdaq Listing Rule 5550(B)(1)
Reuters · 05/17 11:37
Maxim Group Sticks to Its Hold Rating for Agile Therapeutics (AGRX)
TipRanks · 05/13 16:45
BRIEF-Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
Reuters · 05/11 20:48
Agile Therapeutics: Q1 Earnings Insights
Benzinga · 05/11 20:20
Notable earnings after Thursday's close
Seeking Alpha · 05/10 21:35
Agile Therapeutics Q1 2023 Earnings Preview
Seeking Alpha · 05/10 21:35
Agile Therapeutics Earnings Preview
Benzinga · 05/10 15:01
BRIEF-Agile Therapeutics Announces Preliminary Expectations For First Quarter 2023
Reuters · 04/28 13:10
Agile Therapeutics Expects Q1 FY23 Net Revenue Of $3.8M-$4.0M; Total demand Is Expected To Surpass 45,000 total cycles, Up At Least 20% From Q4 FY22 And A Single-Quarter Record
Benzinga · 04/28 12:14
More
Webull provides a variety of real-time AGRX stock news. You can receive the latest news about Agile Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGRX
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.